Literature DB >> 9545711

[Poison and nocebo--2 aspects of toxicology].

E Habermann1.   

Abstract

BACKGROUND: Erroneously it is assumed that drugs promote health exclusively by interacting with the organism through chemical or physical forces. However, placebo phenomena are omnipresent in patients who believe in the value of a treatment, be it medical or paramedical. Conversely, nocebo phenomena originate from fear of detrimental effects attributed to a putative poison. Thus, both drugs and poisons release two different messages, the one being physicochemical, the other psychosocial. The latter is fostered by the public opinion, and man is a sensitive receiver. TYPICAL NOCEBO PHENOMENA: Here some epidemiological examples of nocebo phenomena will be presented. Each society selects the matching nocebos, today mainly as chemical exposures from oecological sources such as environment, buildings, emissions and industrial products. THERAPEUTICAL APPROACH: Suspicion of nocebo should not hamper the search for chemical poisons. Anxiety and fear furnish the neurobiological and evolutionary basis of the nocebo phenomena. Hence behavioural and conversational therapy, supported by antidepressants if needed, should be tried. Unfortunately, most patients expect their psychosocial problems instead to be declared as chemical.

Entities:  

Mesh:

Year:  1998        PMID: 9545711     DOI: 10.1007/BF03043287

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  8 in total

1.  Illness in Gulf War veterans. Causes and consequences.

Authors:  P J Landrigan
Journal:  JAMA       Date:  1997-01-15       Impact factor: 56.272

Review 2.  [Unconventional concepts in environmental medicine].

Authors:  B Burkhard
Journal:  Versicherungsmedizin       Date:  1996-10-01

Review 3.  [Multiple chemical sensitivity (MCS)--the so-called chemical multiple hypersensitivity].

Authors:  C Wolf
Journal:  Versicherungsmedizin       Date:  1996-10-01

Review 4.  [Sick building syndrome].

Authors:  B Brede-Weisflog
Journal:  Versicherungsmedizin       Date:  1996-10-01

5.  Adverse nondrug reactions.

Authors:  M M Reidenberg; D T Lowenthal
Journal:  N Engl J Med       Date:  1968-09-26       Impact factor: 91.245

6.  Mass psychogenic illness: some clarification and perspectives.

Authors:  M J Colligan
Journal:  J Occup Med       Date:  1981-09

7.  Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.

Authors:  A I Goldberg; M C Dunlay; C S Sweet
Journal:  Am J Cardiol       Date:  1995-04-15       Impact factor: 2.778

8.  Adverse nondrug reactions: an update.

Authors:  F P Meyer; U Tröger; F W Röhl
Journal:  Clin Pharmacol Ther       Date:  1996-09       Impact factor: 6.875

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.